The British journal The Lancet confirmed that all 108 people who received the Chinese vaccine produced antibodies.
This recombinant vaccine uses a modified defective adenovirus as vector. The current data show a very low mutation probability of the gene that the team selected from the virus to make the vaccine.
Even if the chosen gene mutates, weakening the vaccine’s protective effect, the vaccine can still achieve basic immunity, and China can quickly develop a vaccine specifically targeting the mutation to enhance the immunity effect
“It’s like upgrade and patch for software,” said Chen, who is also a member of the Chinese Academy of Engineering.